Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 28Lung Neoplasms 27Neoplasm Metastasis 26Carcinoma, Non-Small-Cell Lung 21Multiple Myeloma 18Urinary Bladder Neoplasms 16Breast Neoplasms 16Lymphoma 15Glioma 14Colorectal Neoplasms 14Pancreatic Neoplasms 13Lymphoma, Large B-Cell, Diffuse 13Carcinoma, Renal Cell 13Squamous Cell Carcinoma of Head and Neck 12Ovarian Neoplasms 12Melanoma 12Triple Negative Breast Neoplasms 11Glioblastoma 10Oropharyngeal Neoplasms 9Mouth Neoplasms 9Fallopian Tube Neoplasms 9Carcinoma 9Sarcoma 8Lymphoma, Non-Hodgkin 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Medulloblastoma 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Carcinoma, Hepatocellular 7

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡